公开(公告)号：US20030162690A1

公开(公告)日：2003-08-28

申请号：US10126976

申请日：2002-04-22

Applicant: COR Therapeutics, Inc.

Inventor： Bing-Yan Zhu ,  Penglie Zhang ,  Lingyan Wang ,  Wenrong Huang ,  Erick A. Goldman ,  Wenhao Li ,  Jingmei Zuckett ,  Yonghong Song ,  Robert M. Scarborough

IPC: A61K031/00

CPC classification number: A61K31/44 ,  A61K9/20 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/48 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/616 ,  A61K45/06 ,  A61K2201/094 ,  C07C237/42 ,  C07C255/60 ,  C07C257/18 ,  C07C259/18 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C317/44 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D217/22 ,  C07D231/12 ,  C07D233/56 ,  C07D233/64 ,  C07D249/08 ,  C07D295/125 ,  C07D333/38 ,  C07D401/12 ,  C07D409/12 ,  C07D409/14

Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described Compositions containing such compounds are also described The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders

Abstract translation: 描述了包含其对哺乳动物因子Xa具有活性的其药学上可接受的异构体，盐，水合物，溶剂合物和前药衍生物的新型苯甲酰胺化合物。还描述了含有这些化合物的组合物。化合物和组合物可用于体外或体内用于预防或治疗凝血障碍

公开(公告)号：US20030018184A1

公开(公告)日：2003-01-23

申请号：US10127691

申请日：2002-04-23

Applicant: COR THERAPEUTICS, INC.

Inventor： Johan Sundelin ,  Robert M. Scarborough

IPC: C07K014/715 ,  C07H021/04 ,  C12P021/02 ,  C12N005/06

CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K48/00 ,  C07K7/08 ,  C07K14/705 ,  C07K14/723 ,  G01N2333/726 ,  G01N2500/00

Abstract: Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyte. The nucleic acid molecules are useful in an assay for detecting a substance which affects C140 receptor activity, either receptor agonists or antagonists. Further, the elucidation of the structure of the C140 receptor permits the design of agonist and antagonist compounds which are useful in such assays. The availability of the C140 receptor also permits production of antibodies specifically immunoreactive with one or more antigenic epitopes of the C140 receptor.

Abstract translation: 编码C140细胞表面受体的核酸分子已被克隆并测序。 C140受体DNA的可用性允许重组产生可在细胞表面（包括卵母细胞）上产生的C140受体。 核酸分子可用于检测影响C140受体活性的物质，即受体激动剂或拮抗剂。 此外，阐明C140受体的结构允许设计可用于此类测定中的激动剂和拮抗剂化合物。 C140受体的可用性还允许产生与C140受体的一个或多个抗原表位特异性免疫反应的抗体。